What are the appropriate unfractionated heparin bolus and subcutaneous maintenance doses for a patient who is not receiving an IV infusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Unfractionated Heparin Dosing Without IV Infusion

For therapeutic anticoagulation without IV infusion, administer subcutaneous unfractionated heparin with an initial dose of 333 U/kg followed by 250 U/kg every 12 hours, without routine aPTT monitoring. This fixed-dose, weight-based regimen is as effective and safe as low-molecular-weight heparin for treating venous thromboembolism and is suitable for outpatient management 1, 2.

Therapeutic Anticoagulation Regimens

Subcutaneous UFH for VTE Treatment

The evidence strongly supports fixed-dose subcutaneous heparin:

  • Initial bolus: 333 U/kg subcutaneously
  • Maintenance: 250 U/kg subcutaneously every 12 hours
  • No aPTT monitoring required with this weight-based approach 1

The FIDO trial demonstrated this regimen achieved equivalent outcomes to LMWH, with recurrent VTE rates of 3.8% vs 3.4% and major bleeding of 1.1% vs 1.4% 1. Importantly, 72% of patients were treated entirely as outpatients 1.

Alternative FDA-Approved Regimen

The FDA label provides an alternative approach 3:

  • Initial dose: 5,000 units IV bolus, followed by 10,000-20,000 units subcutaneously
  • Maintenance options:
    • 8,000-10,000 units every 12 hours, OR
    • 15,000-20,000 units every 8 hours

This traditional regimen requires aPTT monitoring 4-6 hours after injection, targeting 1.5-2.0 times control (50-70 seconds) 4, 3.

VTE Prophylaxis Dosing

For hospitalized patients requiring prophylaxis:

  • Standard dose: 5,000 units subcutaneously every 8-12 hours 5, 6
  • Duration: Continue throughout hospitalization or until fully ambulatory 5
  • No routine monitoring needed for prophylactic dosing 5

The every-8-hour regimen appears more effective than every-12-hour dosing, though both are used 7.

Special Populations

Renal Impairment (ESRD)

For patients with end-stage renal disease where LMWH is contraindicated:

  • Use fixed-dose subcutaneous UFH: approximately 223-245 U/kg every 12 hours
  • No monitoring required
  • LMWH accumulates dangerously with CrCl <30 mL/min, making UFH the preferred option 8

Obesity

Critical caveat: Obese patients require lower weight-adjusted doses to achieve target anticoagulation. Body mass index was the only significant predictor of heparin response after weight-based dosing 9. Consider using actual body weight but anticipate achieving therapeutic levels with lower U/kg doses.

Pregnancy

For hospitalized antepartum patients receiving prophylaxis:

  • First trimester: 5,000 units every 12 hours
  • Second trimester: 7,500 units every 12 hours
  • Third trimester: 10,000 units every 12 hours

Important warning: With 7,500-10,000 units every 12 hours, 15-19% of patients develop aPTT >40 seconds, which may impact neuraxial anesthesia timing 10.

Key Advantages of Subcutaneous UFH

  1. Suitable for outpatient treatment - no hospitalization required 1
  2. No routine monitoring needed with fixed weight-based dosing 1, 2
  3. Preferred in severe renal failure (CrCl <30 mL/min) over LMWH 6, 8
  4. Cost-effective alternative to LMWH 8
  5. Rapid reversibility with protamine if needed

Critical Monitoring Requirements

Even without aPTT monitoring for dose adjustment:

  • Platelet counts: Every 2-3 days from day 4-14 to screen for heparin-induced thrombocytopenia (HIT risk up to 5%) 11
  • Hemoglobin/hematocrit: Every 2-3 days up to day 14 6
  • Occult blood in stool: Periodically throughout therapy 4

When to Avoid Subcutaneous UFH

Absolute contraindications 5:

  • Active major bleeding (>2 units transfused in 24 hours)
  • Recent CNS bleed or high-risk intracranial/spinal lesion
  • Concurrent spinal anesthesia/lumbar puncture

Relative contraindications 5:

  • Thrombocytopenia (platelets <50,000/mcL)
  • Severe platelet dysfunction
  • Recent major surgery at high bleeding risk

Practical Administration

  • Use deep subcutaneous injection in the abdominal fat layer (above iliac crest) or upper thigh 4, 3
  • Rotate injection sites to prevent hematoma formation 3
  • Use fine needle (25-26 gauge) to minimize tissue trauma 3
  • Never use intramuscular route - high risk of hematoma 4

Bridging to Warfarin

When transitioning to warfarin:

  • Start warfarin concurrently with heparin
  • Continue full-dose heparin for minimum 5 days AND until INR therapeutic (2-3) for 2 consecutive days 4
  • No tapering required - discontinue abruptly once INR therapeutic 4, 3

Important: Warfarin directly increases aPTT by approximately 20 seconds for each 1.0 increase in INR, which can confuse monitoring if using aPTT-adjusted dosing 12.

References

Guideline

venous thromboembolic disease.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Research

Heparin Dosing During Percutaneous Coronary Intervention and Obesity.

Journal of cardiovascular pharmacology, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.